2011 – FDA: Actos raises risk for bladder cancer by 430%
A 2011 article published in Diabetes Care by C. Piccinni et al. titled “Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.” set out to “analyze the...
View Article2012 – Actos shown to increase risk for bladder cancer
In 2012, a study was published titled “Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.” that aimed to evaluate the connection between the...
View Article2014 – Actos users 14% more likely to develop bladder cancer
In 2014, a team of researchers led by SM Jin published the results of a study that aimed to determined if low doses of pioglitazone (Actos) also raised the risk for bladder cancer among diabetic...
View Article2013 – Large study shows Actos raises risk for bladder cancer 30%
In 2013, a team of researchers led by MT Bazelier published a paper titled “Use of thiazolidinediones and risk of bladder cancer: disease or drugs?”, where it is stated “Pioglitazone, a drug for the...
View Article2011 – Doctor to advocate for Actos paid by manufacturer
In 2011, Robert Elford Ryder published a report in the medical journal The Lancet titled “Pioglitazone and bladder cancer” which discusses the link between diabetes drug Actos (Tadeka Pharmaceuticals,...
View ArticleActos Manufacturers Slated to Pay $9 Billion in Damages
Recently, a federal court has ordered that the manufacturers of the diabetes drug Actos (pioglitazone hydrochloride, by Takeda Pharmaceutical Co. and Eli Lilly & Co.) pay $9 billion in damages when...
View Article2013 – Actos associated with 56% increased risk for bladder cancer
A recent article published in the August, 2013 edition of Hepatology by CH Chang et al. titled “Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus”...
View Article2012 – Long-term Actos use raises risk for bladder cancer 60-80%
In 2012, an article was published in Urology titled “Association between pioglitazone and urothelial bladder cancer.” by Y. Barbalat et al. that aimed to “present the current literature reporting the...
View Article2012 –“Bladder cancer is a real risk with [Actos]”
A recent article published as an editorial in Diabetes Research and Clinical Practice by JA Johnson et al. titled “Balancing the risks and benefits for pioglitazone in type 2 diabetes.” set out to...
View ArticleActos Manufacturer to Pay Millions in Cancer Lawsuit Settlement
Last week, the pharmaceutical company, Takeda, was ordered to pay $1.3 million in punitive damages to a former Philadelphia schoolteacher who “argued the drugmaker’s Actos diabetes medicine caused his...
View Article
